pital day 28, and CT identified a gallbladder stone without any abdominal symptoms.
We considered the possibility of ceftriaxone-associated pseudolithiasis and changed pharmacotherapy to cefmetazole. CT on day 34 showed a reduction in the size of the gallbladder stone. Ceftriaxone-associated pseudolithiasis might arise in the absence of abdominal symptoms, and clinicians should take the patient background and season into account when using this agent.
K E Y W O R D S
asymptomatic, ceftriaxone, high temperature, pseudolithiasis F I G U R E 1 A, Abdominal CT on admission shows no gallbladder stone. B, Abdominal CT on hospital day 28 (during ceftriaxone treatment) clearly shows a gallbladder stone (arrowhead). C, CT on hospital day 34 (after discontinuation of ceftriaxone) shows a reduction in size of the gallbladder stone 
| C A S E
An 88-year-old woman with a history of meningioma and dementia was admitted with high fever, appetite loss, nausea, and weight loss in July. Urinalysis showed increased white blood cells and presence of nitrite, and urinary tract infection was suspected. Computed tomography (CT) showed no significant findings ( Figure 1A ). Ceftriaxone was administered at 2 g/d, and urinary findings improved after 14 days. However, inappetence continued. We discussed with the patient and her family the possibility of providing nutrition by percutaneous endoscopic gastrostomy (PEG), and consent was provided.
On hospital day 20, PEG was successfully implemented. We initiated tube feeding by PEG, and her condition remained stable. However, high fever developed on hospital day 28. Urinary tests showed normal results, but C-reactive protein was increased (5.8 mg/dL) in blood tests. CT identified a gallbladder stone ( Figure 1B ), but the patient reported no abdominal symptoms. We considered viral or bacterial infection as a potential cause of high fever. In terms of the gallbladder stone on CT, we considered the possibility of ceftriaxone-associated pseudolithiasis and changed pharmacotherapy to cefmetazole for the bacterial infection. Her general condition improved, and CT on hospital day 34 showed a reduction in the size of the gallbladder stone ( Figure 1C ). She was discharged on hospital day 47.
| D ISCUSS I ON
This case suggests an important clinical issue. Ceftriaxone is a broad-spectrum, third-generation cephalosporin used to treat various infectious diseases. Ceftriaxone is 85%-95% bound to albumin in blood, with 60% excreted unchanged in urine and 40% in bile. As a result, ceftriaxone concentration in bile is 20 to 150 times that in serum. 3 High-concentration ceftriaxone inhibits bile acid excretion, and calcium ions in bile are increased. Ceftriaxone shows high affinity to calcium ions and produces a biliary sludge comprising the calcium salt of ceftriaxone.
3
The first issue to consider in association with this case is that asymptomatic gallbladder stones can form when using ceftriaxone.
The incidence of pseudolithiasis has been reported as between 10.1% and 57.5% [4] [5] [6] [7] , and symptoms occur in a minority of patients (0%-19%). 4, 8, 9 Our patient also had no abdominal symptoms, with the gallbladder stone only found incidentally on CT. Thus, even though ceftriaxone-associated pseudolithiasis can occur, many patients may show no symptoms, so clinician should pay careful attention to this possibility when using ceftriaxone.
Second, patients who have a complicated background may be at greater risk of ceftriaxone-associated pseudolithiasis. Case reports from Japan of ceftriaxone-associated pseudolithiasis in adults are shown in Table 1 . TA B L E 1 (Continued) dehydrated, increasing the susceptibility to ceftriaxone-associated pseudolithiasis, so careful treatment is needed. Japan has an aging society, and increasing use of ceftriaxone with the growing burden of infectious disease is expected. Patients with dementia, relative inactivity, dysfunction of the gastrointestinal tract, and a long-term bedridden state might be at greater risk of asymptomatic gallbladder stone formation when using ceftriaxone.
Third, the summer season might be a risk factor for ceftriaxoneassociated pseudolithiasis. A past report 25 showed that high environmental temperatures may represent an important risk factor for pseudolithiasis in children. In Japan, high temperature is common throughout summer and may induce a loss of body fluids, promoting sludge formation. Closer attention to meteorological conditions may thus be warranted.
In conclusion, ceftriaxone-associated pseudolithiasis might arise in the absence of abdominal symptoms, and clinicians should take into account the patient background and season when determining the dose and duration of use for this agent.
ACK N OWLED G EM ENT
None.
CO N FLI C T O F I NTE R E S T
The authors have stated explicitly that there are no conflicts of inter- 
